Aerovate Therapeutics Files 8-K
Ticker: JBIO · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1798749
| Field | Detail |
|---|---|
| Company | Aerovate Therapeutics, INC. (JBIO) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-event
TL;DR
Aerovate filed an 8-K, something happened but they aren't saying what yet.
AI Summary
Aerovate Therapeutics, Inc. filed an 8-K on April 9, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or dates beyond the filing date itself. The company is incorporated in Delaware and its principal executive offices are located in Waltham, Massachusetts.
Why It Matters
This filing indicates a material event has occurred for Aerovate Therapeutics, Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in this document.
Risk Assessment
Risk Level: medium — The filing of an 8-K often signifies a material event, but the lack of specific details in this report creates uncertainty about the nature and impact of the event.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Waltham, Massachusetts (location) — Principal Executive Offices
- April 9, 2025 (date) — Date of Report
FAQ
What specific event is Aerovate Therapeutics, Inc. reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the event itself.
When was this 8-K filing submitted?
The filing was submitted on April 9, 2025.
Where are Aerovate Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts, 02451.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the IRS Employer Identification Number (EIN) for Aerovate Therapeutics, Inc.?
The IRS Employer Identification Number is 83-1377888.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 regarding Aerovate Therapeutics, Inc. (JBIO).